For many children, asthma can be a constant specter, with attacks at the most inconvenient and terrifying times. New research ...

New guidelines that seek to change how asthma is treated in Australia have been unveiled by Health Minister Mark Butler and ...

In the first randomized controlled trial to investigate the use of a 2-in-1 inhaler as the sole reliever therapy for children ...

Please provide your email address to receive an email when new articles are posted on . “Asthma care in the Netherlands is divided between different health care providers, including respiratory ...

A joint scientific study conducted by researchers at the Medical Research Institute of New Zealand, in collaboration with ...

A groundbreaking international study has shown that a 2-in-1 budesonide-formoterol inhaler is far more effective than the ...

Australia has overhauled the way asthma is treated, with doctors advised to stop prescribing blue “reliever” puffers alone amid evidence they leave patients at greater risk of severe attacks.

The National Asthma Council’s advice for treating the condition has been updated, advising doctors against solely prescribing blue puffers to patients.

Among pediatric patients with intermittent asthma, around one-third did not have significant acute care needs over a 2-year ...

Children with mild asthma at low risk for severe exacerbations may not need daily or as-needed ICS, as GINA guidelines recommend.

Findings could redefine the treatment for millions of children worldwide with asthma, after this comparison of two types of asthma inhalers.